There are also indications that DUSP2/MKP-4 is implicated in resistance to chemotherapy in both gastric cancer, where resistance to doxorubicin is associated with DUSP4/MKP-2 driven epithelial-mesenchymal transition (EMT) [106] and in Her2 positive breast cancer where DUSP4/MKP-2 is associated with resistance to the anti-Her2 humanised monoclonal antibody Trastuzumab and siRNA mediated silencing of DUSP4/MKP-2 re-sensitised breast cancer cell lines with an amplified Her2 oncogene to this agent [107]. Here, DUSP4 is linked to breast carcinoma.